No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
New Indication Alert: Chugai/Zenyaku’s Rituximab Approved in Japan for Nephrotic Syndrome
On 27 March 2025, Chugai (a Roche subsidiary) and Zenyaku Kogyo announced that their co-marketed Rituxan® (rituximab) has been approved by the Japanese Ministry of Health, Labour and Welfare…